Bolt Biotherapeutics, Inc. Capital Expenditures
Bolt Biotherapeutics, Inc. (BOLT) reported Capital Expenditures of $13.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-11
- Bolt Biotherapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $0.00.
- Bolt Biotherapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $72.00K, a 75.61% increase year-over-year.
- Bolt Biotherapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- Bolt Biotherapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2024-09-30 was $41.00K, a 75.15% decline year-over-year.
- Bolt Biotherapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2025 was $72.00K, a 75.61% increase from fiscal 2024.
- Bolt Biotherapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2024 was $41.00K, a 80.10% decline from fiscal 2023.
- Bolt Biotherapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2023 was $206.00K, a 89.45% decline from fiscal 2022.
- Bolt Biotherapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2022 was $1.95M, a 16.47% decline from fiscal 2021.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2026-06-30 | $13.00K 10-Q · filed 2026-08-11 | |||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $72.00K derived: sum of 2 quarters · filed 2026-03-12 | $72.00K 10-K · filed 2026-03-12 | |
| 2025-09-30 | $72.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $72.00K 10-Q · filed 2025-11-12 | ||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-11 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $41.00K derived: sum of 2 quarters · filed 2026-03-12 | $41.00K derived: sum of 3 quarters · filed 2026-03-12 | $41.00K 10-K · filed 2026-03-12 |
| 2024-09-30 | $41.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $41.00K derived: sum of 2 quarters · filed 2025-11-12 | $41.00K 10-Q · filed 2025-11-12 | $47.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $0.00 10-Q · filed 2024-08-13 | $6.00K derived: sum of 3 quarters · filed 2025-03-24 | $171.00K derived: sum of 4 quarters · filed 2025-03-24 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-14 | $6.00K derived: sum of 2 quarters · filed 2025-03-24 | $171.00K derived: sum of 3 quarters · filed 2025-03-24 | $203.00K derived: sum of 4 quarters · filed 2025-03-24 |
| 2023-12-31 | $6.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $171.00K derived: sum of 2 quarters · filed 2025-03-24 | $203.00K derived: sum of 3 quarters · filed 2025-03-24 | $206.00K 10-K · filed 2025-03-24 |
| 2023-09-30 | $165.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $197.00K derived: sum of 2 quarters · filed 2024-11-12 | $200.00K 10-Q · filed 2024-11-12 | $384.00K derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $32.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $35.00K 10-Q · filed 2024-08-13 | $219.00K derived: sum of 3 quarters · filed 2024-08-13 | $954.00K derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $3.00K 10-Q · filed 2024-05-14 | $187.00K derived: sum of 2 quarters · filed 2024-05-14 | $922.00K derived: sum of 3 quarters · filed 2024-05-14 | $1.35M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $184.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $919.00K derived: sum of 2 quarters · filed 2024-03-21 | $1.35M derived: sum of 3 quarters · filed 2024-03-21 | $1.95M 10-K · filed 2024-03-21 |
| 2022-09-30 | $735.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $1.16M derived: sum of 2 quarters · filed 2023-11-09 | $1.77M 10-Q · filed 2023-11-09 | $2.33M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $429.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $1.03M 10-Q · filed 2023-08-07 | $1.60M derived: sum of 3 quarters · filed 2023-08-07 | $2.61M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $605.00K 10-Q · filed 2023-05-11 | $1.17M derived: sum of 2 quarters · filed 2023-05-11 | $2.18M derived: sum of 3 quarters · filed 2023-05-11 | $2.88M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $562.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $1.58M derived: sum of 2 quarters · filed 2023-03-29 | $2.28M derived: sum of 3 quarters · filed 2023-03-29 | $2.34M 10-K · filed 2023-03-29 |
| 2021-09-30 | $1.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $1.72M derived: sum of 2 quarters · filed 2022-11-10 | $1.78M 10-Q · filed 2022-11-10 | $2.67M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $703.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $761.00K 10-Q · filed 2022-08-10 | $1.66M derived: sum of 3 quarters · filed 2022-08-10 | $2.81M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $58.00K 10-Q · filed 2022-05-12 | $956.00K derived: sum of 2 quarters · filed 2022-05-12 | $2.11M derived: sum of 3 quarters · filed 2022-05-12 | $2.95M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $898.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $2.05M derived: sum of 2 quarters · filed 2022-03-30 | $2.89M derived: sum of 3 quarters · filed 2022-03-30 | $3.26M 10-K · filed 2022-03-30 |
| 2020-09-30 | $1.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $1.99M derived: sum of 2 quarters · filed 2021-11-09 | $2.36M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $840.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $1.21M 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $373.00K 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |